[citation needed] Shortly after the COVID-19 outbreak in Kazakhstan, Erlan Ramanqūlov, the Director General of the National Center for Biotechnology announced in April 2020 the stages on developing the COVID-19 vaccine, acknowledging that clinical trials usually take up to 10 years to develop and that all verified research process would be cut short due to the intense situation in the country, expediting the coronavirus vaccine production and forecasted that it would be available to the public within the next year and a half.

[1] On 18 May 2020, the Ministry of Education and Science announced that the preclinical trials for the local COVID-19 vaccine had begun of which was developed by the employees of the Research Institute of Biological Safety Problems of the Science Committee (BQPĞZÏ) under the Ministry by the strain of the coronavirus isolated from patients and that the World Health Organization (WHO) had registered the vaccine development.

[2] At the cabinet meeting, Education and Science Minister Ashat Aimagambetov announced that five COVID-19 vaccines were being developed and that the preclinical trials would be tested on animals until September 2020, when the clinical stages would begin for humans.

[3] In August 2020, the National Center for Expertise of Medicines and Medical Devices reported that the QazCovid-in vaccine showed no dangers during preclinical study stage and ruled that the testing could advance further into clinical trials on humans.

[5] In December 2020, the Ministry of Healthcare approved the final phase III of clinical trials by the BQPĞZI for 3,000 volunteers, by which the institute reported 96% efficiency rate of QazCovid-in.